V
VOR
Vor Biopharma Inc.
18.26
-0.68-3.59%After Hours: 18.25 -0.01 -0.05%17:57 10/23 EDT
OPEN/PREV CLOSE18.67/18.94
TODAY RANGE17.95-18.81
VOL720.95K
MARKET CAP1.08B
52 WEEK RANGE6.50-30.40
AVG VOL (3M)954.18K
% TURNOVER0.98%
TURNOVER--
P/E (TTM)-0.4246
% RANGE4.49%
EPS(TTM)-43.0024
P/E(FORWARD)-2.5164
P/B-4.9670
BVPS-3.6763
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP934.63M
SHARES OUTSTANDING59.16M
NEXT EARNINGS11/11-11/16
FREE FLOAT51.18M
LOT SIZE1
EX-DATE09/19/2025
News
Press Releases
Financial Reports
Profile
Simply Wall St·7h ago
Learn Why The Bull Case For Vor Biopharma Stock Could Change Following Phase 3 Kidney Trial Results
Dow Jones·2d ago
Vor Biopharma Initiated at Outperform by William Blair
TipRanks·2d ago
Vor Bio initiated with an Outperform at William Blair
TipRanks·5d ago
Wells Fargo Keeps Their Buy Rating on Vor Biopharma (VOR)
TipRanks·10/15 11:56
Citi Sticks to Its Buy Rating for Vor Biopharma (VOR)
Simply Wall St·10/11 23:32
How Investors May Respond To Vor Biopharma (VOR) Phase 3 gMG Data
Simply Wall St·10/08 08:28
Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 Data Strengthens Its Case
Simply Wall St·10/04 22:20
Long Lasting Symptom Relief Data Could Be A Game Changer For Vor Biopharma Stock
Simply Wall St·10/01 04:23
Vor Biopharma (VOR) Could Be 51% Undervalued After Fresh Phase 3 gMG Data
TipRanks·09/28 10:56
Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus
Seeking Alpha·09/18 08:48
Vor Biopharma: A Funded Replication Story With Franchise Potential
Simply Wall St·09/17 05:25
Is Phase 3 Enrollment Complete Altering The Investment Case For Vor Biopharma (VOR)?
Same Industry
Name/Symbol
Change%
Price